
|Articles|May 1, 2003
Allergy agent more potent in inhibition of IL-6, tryptase
Author(s)Theorharis Theorharides, MD, Lynda Charters
Boston-Ophthalmic solutions of azelastine HCl (Optivar, Asta Medica/Muro Pharmaceutical Inc., Tewksbury, MA) and olopatadine HCl (Patanol, Alcon Laboratories, Fort Worth, TX) both effectively inhibit the activation of normal cultured human mast cells and the release of interleukin-6 (IL-6), tryptase, and histamine. However, azelastine seemed to be substantially more potent for treating ocular allergy when the two drugs were compared in an in vitro study.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
Reasoning prompts sharpen multimodal AI on bilingual ophthalmology exam questions
3
TECNIS PureSee IOL launches in US following FDA approval for cataract surgery
4
Beyond the Walls: Leading with love, loyalty, and a team first philosophy with Vance Thompson, MD
5





















